SURE-02: Neoadjuvant SG/Pembro, Response-Adapted Bladder Sparing, and Adjuvant Pembro for MIBC

26 Visioni
Published
Andrea Necchi, MD, San Raffaele Hospital and Scientific Institute, and Karine Tawagi, MD, University of Illinois, break down in detail the first results of SURE-02, which was a phase II study of neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by response-adapted bladder sparing and adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer.
Categoria
Oncology
Commenta per primo questo video.